These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 6616601)

  • 21. Relatively slow and long-lasting antimigraine effect of dihydroergotamine is most likely due to basic pharmacological attributes of the drug: a review.
    Tfelt-Hansen PC
    Cephalalgia; 2013 Oct; 33(13):1122-31. PubMed ID: 23588793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Migraine prevention with dihydroergotamine].
    Heuser B; Middendorf E
    Fortschr Med; 1985 Nov; 103(41):966-70. PubMed ID: 3905548
    [No Abstract]   [Full Text] [Related]  

  • 23. Where is dihydroergotamine mesylate in the changing landscape of migraine therapy?
    Morren JA; Galvez-Jimenez N
    Expert Opin Pharmacother; 2010 Dec; 11(18):3085-93. PubMed ID: 21080856
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Dihydroergotamine as a nasal spray in the therapy of migraine attacks. Efficacy and tolerance].
    Jenzer G; Bremgartner MF
    Schweiz Rundsch Med Prax; 1990 Aug; 79(31-32):914-7. PubMed ID: 2203127
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment of transformed refractory migraine with intravenous dihydroergotamine].
    Cid C; Ortega-Valín F; Valero M; Muñoz R; Pascual J
    Neurologia; 1999; 14(6):315-8. PubMed ID: 10439626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment of morning migraine. Clinical and biokinetic correlation of programmed-release dihydroergotamine].
    Aylward M; Chazot G; Maddock J; Schott B
    Presse Med; 1984 Jun; 13(26):1617-9. PubMed ID: 6234558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is orally inhaled dihydroergotamine (DHE) equivalent in efficacy in migraine to intravenous DHE?
    Tfelt-Hansen P
    Headache; 2014 Feb; 54(2):383. PubMed ID: 24512579
    [No Abstract]   [Full Text] [Related]  

  • 28. Dihydroergokryptine versus dihydroergotamine in migraine prophylaxis: a double-blind clinical trial.
    Frediani F; Grazzi L; Zanotti A; Mailland F; Zappacosta BM; Bussone G
    Cephalalgia; 1991 Jul; 11(3):117-21. PubMed ID: 1909603
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine.
    Aurora SK; Rozen TD; Kori SH; Shrewsbury SB
    Headache; 2009 Jun; 49(6):826-37. PubMed ID: 19545249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dihydroergotamine nasal spray during migraine attacks. A double-blind crossover study with placebo.
    Tulunay FC; Karan O; Aydin N; Culcuoglu A; Guvener A
    Cephalalgia; 1987 Jun; 7(2):131-3. PubMed ID: 3301001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Orally inhaled dihydroergotamine: a review.
    Tepper SJ
    Headache; 2013 Sep; 53 Suppl 2():43-53. PubMed ID: 24024602
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical pharmacological aspects of dihydroergotamine timed release: activity on monoamine venospasm.
    Franchi G; Anselmi B; Del Bianco PL; Panconesi A; Sicuteri F
    Cephalalgia; 1983 Aug; 3 Suppl 1():185-8. PubMed ID: 6616602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Symptomatic and prophylactic treatment of migraine and tension-type headache.
    Schulman EA; Silberstein SD
    Neurology; 1992 Mar; 42(3 Suppl 2):16-21. PubMed ID: 1557187
    [TBL] [Abstract][Full Text] [Related]  

  • 35. STOP 301: A Phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD
    Smith TR; Winner P; Aurora SK; Jeleva M; Hocevar-Trnka J; Shrewsbury SB
    Headache; 2021 Sep; 61(8):1214-1226. PubMed ID: 34363701
    [TBL] [Abstract][Full Text] [Related]  

  • 36. On the treatment of migraine. Pharmacokinetic-pharmacodynamic relationships for a programmed release formulation of dihydroergotamine administered orally in the human.
    Aylward M; Davies DE; Maddock J; Robinson PR; Jones M
    Cephalalgia; 1983 Aug; 3 Suppl 1():146-50. PubMed ID: 6616596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dihydroergotamine and its metabolite, 8'-hydroxy-dihydroergotamine, as 5-HT1A receptor agonists in the rat brain.
    Hanoun N; Saurini F; Lanfumey L; Hamon M; Bourgoin S
    Br J Pharmacol; 2003 May; 139(2):424-34. PubMed ID: 12770948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Calcium carbasalate-metoclopramide combination versus dihydroergotamine in the treatment of migraine attacks].
    Pradalier A; Guérard des Lauriers A; Scheck F; Peraudeau P; Lacoste JP; Cajfinger F
    Pathol Biol (Paris); 1995 Nov; 43(9):806-13. PubMed ID: 8746103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis--a double-blind, multicentre, randomized placebo-controlled dose-response study.
    Pfaffenrath V; Diener HC; Fischer M; Friede M; Henneicke-von Zepelin HH;
    Cephalalgia; 2002 Sep; 22(7):523-32. PubMed ID: 12230594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DHE in the pharmacotherapy of migraine: potential for a larger role.
    Saper JR; Silberstein S; Dodick D; Rapoport A
    Headache; 2006 Nov; 46 Suppl 4():S212-20. PubMed ID: 17078853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.